Earlier this year, Sirona acted as commercial advisor to Navamedic in connection with its investment in Swedish pharma company Sensidose.
Sensidose has developed a system for individualized dosing through micro-tablets for Parkinson's patients. By offering individualized dosing for each patient, the treatment can be tailored to each individual's unique conditions, which will contribute to increased quality of life for the patient.
Congratulations on the new partnership, we look forward to following your exciting journey!
Want to know more about how Sirona works with due diligence and commercial advice? Contact Sirona's Director of Private Equity and Life Sciences, Shadi Abbas.
